126 related articles for article (PubMed ID: 9142975)
1. Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review.
Sjöström J; Blomqvist C
Acta Oncol; 1996; 35 Suppl 5():84-90. PubMed ID: 9142975
[No Abstract] [Full Text] [Related]
2. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
3. [Prognostic and predictive factors for endocrine treatment in breast carcinoma].
Knoop AS; Rasmussen BB
Ugeskr Laeger; 2007 Sep; 169(36):2997-9. PubMed ID: 17953880
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategy for metastatic breast cancer according to intrinsic subtype.
Noguchi S
Int J Clin Oncol; 2010 Aug; 15(4):333-4. PubMed ID: 20632058
[No Abstract] [Full Text] [Related]
5. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
Ellis MJ
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
[No Abstract] [Full Text] [Related]
6. [San Antonio Breast Cancer Symposium 2003. New therapeutic prospects in the treatment of early-stage breast cancer].
Montemurro F
Tumori; 2004; 90(1):suppl 1-16. PubMed ID: 15143995
[No Abstract] [Full Text] [Related]
7. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
8. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
[TBL] [Abstract][Full Text] [Related]
9. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
[TBL] [Abstract][Full Text] [Related]
10. Lurbinectedin for BRCA-mutated advanced breast cancer.
Gourd E
Lancet Oncol; 2018 Nov; 19(11):e582. PubMed ID: 30269906
[No Abstract] [Full Text] [Related]
11. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
12. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic endpoints in primary breast cancer.
Di Cosimo S; Baselga J
Ann Oncol; 2007 Jul; 18 Suppl 9():ix21-3. PubMed ID: 17631590
[No Abstract] [Full Text] [Related]
14. Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer.
Nie C; Lv H; Bie L; Hou H; Chen X
Medicine (Baltimore); 2018 Dec; 97(51):e13551. PubMed ID: 30572455
[TBL] [Abstract][Full Text] [Related]
15. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines are a critical component of adjuvant chemotherapy regimens for high-risk early breast cancer.
Morris PG; Hudis CA; Dang CT
Oncology (Williston Park); 2011 Feb; 25(2):134-5, 138, 140. PubMed ID: 21456384
[No Abstract] [Full Text] [Related]
18. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
Fujita T; Doihara H; Kawasaki K; Takabatake D; Takahashi H; Washio K; Tsukuda K; Ogasawara Y; Shimizu N
Br J Cancer; 2006 Jan; 94(2):247-52. PubMed ID: 16404430
[TBL] [Abstract][Full Text] [Related]
19. Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.
Avan A; Avan A; Maftouh M; Ghayour Mobarhan M; Shahidsales S; Gholamin S
J Clin Oncol; 2015 May; 33(15):1711-2. PubMed ID: 25870088
[No Abstract] [Full Text] [Related]
20. What is the value of the 21 gene recurrence score in HER2-negative patients?
Rosman M; Mylander WC; Tafra L
J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
[No Abstract] [Full Text] [Related]
[Next] [New Search]
